The directors of a company that is perfecting a range of cancer vaccines have taken the business to PLUS in a bid to continue the development of its products.

The directors of a company that is perfecting a range of cancer vaccines have taken the business to PLUS in a bid to continue the development of its products.

Scancell has been valued at £6.1 million after its shares started trading on the market at 60p each. The move has given the company access to future working capital.

The spin-off from Nottingham University’s Department of Clinical Oncology focuses on the discovery and development of products that use the immune system to treat or prevent cancer.

Scancell’s corporate adviser was St Helen’s Capital, while Laytons provided legal services. Laytons has supported the company on various matters for several years. Its team on this transaction was led by Richard Kennett and Emma Langdon.

Kennett and Langdon worked on a reconstruction prior to the placing to create a new holding company, including reorganisation of the firm’s share capital, and also liaised with its 50 shareholders.